Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Musculoskelet Neuronal Interact ; 19(3): 253-257, 2019 09 01.
Article in English | MEDLINE | ID: mdl-31475931

ABSTRACT

OBJECTIVES: Noggin inactivates bone morphogenetic proteins (BMPs), possibly exerting negative effects on the skeleton.We aimed to compare the effect of agents with opposite impact on bone turnover on noggin circulating levels. METHODS: In this observational, open label, non-randomized clinical study postmenopausal women with low bone mass were treated with either denosumab (n=30) or teriparatide (n=30). Serum samples were obtained at baseline, three and twelve months after treatment initiation. Prevalent fractures were recorded at baseline and lumbar spine bone mineral density (LS BMD) was measured at baseline and twelve months. Measured parameters included noggin, BMP-2, BMP-4, procollagen type 1 N-terminal propeptide (P1NP) and C-terminal cross-linking telopeptide of type 1 collagen (CTx). RESULTS: Noggin levels remained unchanged after either denosumab or teriparatide treatment. Baseline noggin levels were not different between women with vs. without previous anti-osteoporotic treatment, or between those with vs. without vertebral or non-vertebral fractures and were not correlated with age or LS BMD. At twelve months, noggin levels were positively correlated with P1NP within the denosumab (rs= 0.47; p=0.014), whereas negatively within the teriparatide group (rs= -0.43; p=0.019). CONCLUSIONS: In postmenopausal women with low bone mass noggin levels were not correlated with bone parameters at any time point, except with P1NP at 12 months, and remained stable with both denosumab and teriparatide treatment.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Carrier Proteins/blood , Denosumab/therapeutic use , Osteoporosis, Postmenopausal/blood , Osteoporosis, Postmenopausal/drug therapy , Teriparatide/therapeutic use , Aged , Aged, 80 and over , Female , Humans , Middle Aged
2.
Hematology ; 24(1): 318-324, 2019 Dec.
Article in English | MEDLINE | ID: mdl-30665323

ABSTRACT

INTRODUCTION: Noggin is an antagonist of bone morphogenetic proteins (BMPs) and has a strong effect on osteogenesis. Osteoporosis is a common complication of transfusion dependent beta-thalassemia (TDT) and denosumab has been recently emerged as a promising therapeutic option. This was a post hoc investigation of serum noggin levels among TDT patients with osteoporosis who participated in a randomized, placebo-control, phase 2b study. METHODS: Patients received either 60 mg denosumab (n = 32) or placebo (n = 31) every 6 months for 12 months. Noggin was measured, for the first time in thalassemia patients, at baseline and at 12 months, using a recently developed high sensitivity fluorescent immunoassay. RESULTS: Both groups showed a significant increase in noggin serum levels (denosumab p < 0.001; placebo p < 0.0001). Interestingly, the increase was higher in the placebo group. Furthermore, we observed a strong correlation between noggin and wrist bone mineral density (r = -0.641, p = 0.002) only in the denosumab group. CONCLUSION: In conclusion, higher noggin levels reflected more BMP inhibition, since our assay detects free bioactive noggin, which in turn impaired bone formation in placebo group. Therefore, denosumab possibly regulates noggin and favours bone turnover in TDT patients with osteoporosis through a novel mechanism of action.


Subject(s)
Carrier Proteins/blood , Denosumab/administration & dosage , Osteoporosis/blood , Osteoporosis/drug therapy , Thalassemia/blood , Thalassemia/drug therapy , Adult , Aged , Bone Remodeling/drug effects , Female , Humans , Male , Middle Aged
3.
Hormones (Athens) ; 17(4): 573-579, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30467685

ABSTRACT

AIM: The evaluation of (a) noggin levels in patients with simple steatosis (SS) vs. nonalcoholic steatohepatitis (NASH) vs. controls, and (b) the effect of combined spironolactone plus vitamin E vs. vitamin E monotherapy on noggin levels in biopsy-proven patients with nonalcoholic fatty liver disease (NAFLD). METHODS: In the case-control study, 15 patients with SS, 16 with NASH, and 24 controls were included. In the randomized controlled trial, NAFLD patients were assigned to vitamin E (400 IU/d) or spironolactone (25 mg/d) plus vitamin E for 52 weeks. RESULTS: Noggin levels were lower in SS (5.8 ± 1.5 pmol/l) and NASH (8.7 ± 2.4 pmol/l) patients than in controls (13.7 ± 2.7 pmol/l; p for trend = 0.040), but were similar in SS and NASH patients. After adjustment for potential cofounders, log(noggin) remained different between groups. Log(noggin) levels similarly increased post-treatment in both groups: log(noggin) was not different between groups (p = 0.20), but increased within groups over time (p < 0.001), without a significant group × time interaction (p = 0.62). Log(noggin) significantly increased at month 2 post-treatment (p = 0.008 vs. baseline) and remained stable thereafter. CONCLUSIONS: Lower noggin levels were observed in NAFLD patients than in controls. Noggin levels increased similarly by either combined low-dose spironolactone plus vitamin E or vitamin E monotherapy. TRIAL REGISTRATION: NCT01147523.


Subject(s)
Carrier Proteins/blood , Mineralocorticoid Receptor Antagonists/pharmacology , Non-alcoholic Fatty Liver Disease/blood , Non-alcoholic Fatty Liver Disease/drug therapy , Spironolactone/pharmacology , Vitamin E/pharmacology , Carrier Proteins/drug effects , Case-Control Studies , Drug Therapy, Combination , Humans , Mineralocorticoid Receptor Antagonists/administration & dosage , Spironolactone/administration & dosage , Vitamin E/administration & dosage
4.
SLAS Discov ; 22(8): 1035-1043, 2017 09.
Article in English | MEDLINE | ID: mdl-28277888

ABSTRACT

Celiac disease (CD) is a chronic inflammatory condition caused by the ingestion of gliadin-containing food in genetically susceptible individuals. Undigested peptides of gliadin exert various effects, including increased intestinal permeability and inflammation in the small intestine. Although many therapeutic approaches are in development, a gluten-free diet is the only effective treatment for CD. Affecting at least 1% of the population in industrialized countries, it is important to generate therapeutic options against CD. Here, we describe the establishment of a high-throughput screening (HTS) platform based on AlphaLISA and electrical cell-substrate impedance sensing (ECIS) technology for the identification of anti-inflammatory and barrier-protective compounds in human enterocytes after pepsin-trypsin-digested gliadin (PT-gliadin) treatment. Our results show that the combination of these HTS technologies enables fast, reliable, simple, and label-free screening of IgY antibodies against PT-gliadin. Using this platform, we have identified a new chicken anti-PT-gliadin IgY antibody as a potential anti-CD agent.


Subject(s)
Antibodies, Neutralizing/analysis , Epithelial Cells/cytology , Gliadin/immunology , High-Throughput Screening Assays/methods , Intestines/cytology , Caco-2 Cells , Cell Communication , Cell Survival , Down-Regulation , Humans , Immunoglobulins/isolation & purification , Inflammation/pathology , Interleukin-8/metabolism , NF-kappa B/metabolism , Transcription Factors/metabolism
5.
Sci Rep ; 6: 37253, 2016 11 17.
Article in English | MEDLINE | ID: mdl-27853253

ABSTRACT

Melanoma is the most aggressive type of skin cancer and one of the most frequent tumours in young adults. Identification of primary tumours prone to develop metastasis is of paramount importance for further patient stratification. However, till today, no markers exist that are routinely used to predict melanoma progression. To ameliorate this problem, we generated antiserum directed against metastatic melanoma tissue lysate and applied a novel approach to purify the obtained serum via consecutive affinity chromatography steps. The established antibody, termed MHA-3, showed high reactivity against metastatic melanoma cell lines both in vitro and in vivo. We also tested MHA-3 on 227 melanoma patient samples and compared staining with the melanoma marker S100b. Importantly, MHA-3 was able to differentiate between metastatic and non-metastatic melanoma samples. By proteome analysis we identified 18 distinct antigens bound by MHA-3. Combined expression profiling of all identified proteins revealed a significant survival difference in melanoma patients. In conclusion, we developed a polyclonal antibody, which is able to detect metastatic melanoma on paraffin embedded sections. Hence, we propose that this antibody will represent a valuable additional tool for precise melanoma diagnosis.


Subject(s)
Antibodies, Neoplasm , Antigens, Neoplasm/immunology , Biomarkers, Tumor/immunology , Chromatography, Affinity , Melanoma/immunology , Animals , Antibodies, Neoplasm/chemistry , Antibodies, Neoplasm/immunology , Antibodies, Neoplasm/isolation & purification , Antigens, Neoplasm/chemistry , Biomarkers, Tumor/chemistry , Female , Humans , Melanoma/mortality , Melanoma/pathology , Mice , Mice, SCID , Neoplasm Metastasis , Rabbits
6.
BMC Biotechnol ; 15: 109, 2015 Dec 01.
Article in English | MEDLINE | ID: mdl-26625857

ABSTRACT

BACKGROUND: Celiac disease (CD) is a chronic, small intestinal inflammatory disease mediated by dietary gluten and related prolamins. The only current therapeutic option is maintenance of a strict life-long gluten-free diet, which implies substantial burden for CD patients. Different treatment regimes might be feasible, including masking of toxic celiac peptides with blocking antibodies or fragments thereof. The objective of this study was therefore to select and produce a recombinant avian single-chain fragment variable (scFv) directed against peptic-tryptic digested gliadin (PT-Gliadin) and related celiac toxic entities. RESULTS: Gluten-free raised chicken of same age were immunized with PT-Gliadin. Chicken splenic lymphocytes, selected with antigen-coated magnetic beads, served as RNA source for the generation of cDNA. Chicken VH and VL genes were amplified from the cDNA by PCR to generate full-length scFv constructs consisting of VH and VL fragments joined by a linker sequence. ScFv constructs were ligated in a prokaryotic expression vector, which provides a C-terminal hexahistidine tag. ScFvs from several bacterial clones were expressed in soluble form and crude cell lysates screened for binding to PT-Gliadin by ELISA. We identified an enriched scFv motif, which showed reactivity to PT-Gliadin. One selected scFv candidate was expressed and purified to homogeneity. Polyclonal anti-PT-Gliadin IgY, purified from egg yolk of immunized chicken, served as control. ScFv binds in a dose-dependent manner to PT-Gliadin, comparable to IgY. Furthermore, IgY competitively displaces scFv from PT-Gliadin and natural wheat flour digest, indicating a common epitope of scFv and IgY. ScFv was tested for reactivity to different gastric digested dietary grain flours. ScFv detects common and khorasan wheat comparably with binding affinities in the high nanomolar range, while rye is detected to a lesser extent. Notably, barley and cereals which are part of the gluten-free diet, like corn and rice, are not detected by scFv. Similarly, the pseudo-grain amaranth, used as gluten-free alternative, is not targeted by scFv. This data indicate that scFv specifically recognizes toxic cereal peptides relevant in CD. CONCLUSION: ScFv can be of benefit for future CD treatment regimes.


Subject(s)
Celiac Disease/prevention & control , Gliadin/metabolism , Single-Chain Antibodies/metabolism , Animals , Celiac Disease/metabolism , Chickens , Enzyme-Linked Immunosorbent Assay , Genetic Vectors , Lymphocytes/metabolism , Protein Binding , Single-Chain Antibodies/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...